AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24276047
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EZN-3042 with intensive reinduction chemotherapy
Trial: 24277073
Drug: Imatinib (single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (single-agent course following induction)
Trial: 24277073
Drug: Pre-imatinib standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-imatinib standard treatment
Trial: 24283202
Drug: Ruxolitinib 5
RxNorm normalized name: ruxolitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 5 mg BID, with potential increase to 10 mg BID
Trial: 24283202
Drug: Ruxolitinib 5
RxNorm normalized name: ruxolitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 5 mg BID
Trial: 24284413
Drug: HAV vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccination in patients treated with anti-TNF monoclonal antibody infliximab or adalimumab
Trial: 24284413
Drug: HAV vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccination in patients not treated with anti-TNF agents
Trial: 24284413
Drug: HAV vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccination in patients treated with ≥2 immunosuppressants
Trial: 24284413
Drug: HAV vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccination in patients treated with <2 immunosuppressants
Trial: 24284413
Drug: HAV vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccination comparing anti-TNF alone with anti-TNF and other immunosuppressants
Trial: 24284413
Drug: HAV vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccination in patients receiving anti-TNF therapy
Trial: 24285015
Drug: Doxorubicin HCl
RxNorm normalized name: doxorubicin HCl
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin HCl liposome injection (DLI) 20 mg/m(2) i.v. every 2 weeks for 16 weeks (8 doses) followed by Bexarotene 300 mg/m(2) orally for 16 weeks
Trial: 24285015
Drug: Bexarotene 300
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene 300 mg/m(2) orally for 16 weeks
Trial: 24287082
Drug: Bone Marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone Marrow Mononuclear Cells (BMMC) infusion
Trial: 24287733
Drug: Drug-related skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related skin disorders
Trial: 24289141
Drug: Oral paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral paliperidone extended-release (ER) 3 to 12 mg daily for 26 to 52 weeks
Trial: 24289658
Drug: TIV/10 (seasonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIV/10 (seasonal trivalent inactivated vaccine 2010)
Trial: 24289658
Drug: Monovalent AS03-adjuvanted
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine
Trial: 24289796
Drug: Oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administration during labor
Trial: 24291380
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor (AI) therapy
Trial: 24293774
Drug: Depot GnRHa
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot GnRHa (leuprolide 3.75-mg)
Trial: 24294924
Drug: Inhaled budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide, 800 ug/day
Trial: 24295437
Drug: Histrelin implant
RxNorm normalized name: histrelin Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histrelin implant (50-mg subcutaneous annually)
Trial: 24295572
Drug: Vorinostat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (100 mg or 200 mg, twice a day) initiated 10 days before haemopoietic stem-cell transplantation until day 100, in combination with standard immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28) and tacrolimus (0.03 mg/kg a day, titrated to a goal level of 8-12 ng/mL, starting day -3 until day 180)
Trial: 24296713
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose stimulation
Trial: 24297771
Drug: Late PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late PCI with optimal medical therapy (OMT)
Trial: 24297953
Drug: Fractionated (90)Y-ibritumomab
RxNorm normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fractionated (90)Y-ibritumomab tiuxetan (90Y-IT) administered in two doses of 11.1 MBq/kg, 8 to 12 weeks apart.
Trial: 24298176
Drug: Thrombolysis administered
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis administered within 90 minutes of ictus
Trial: 24303954
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of biofilm pathogens and GCF biomarkers with clinical measures
Trial: 24304924
Drug: Foods with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foods with added fiber (23 g/d)
Trial: 24307695
Drug: High-throughput sequencing
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-throughput sequencing (HTS) of T cell receptors (TCRB)
Trial: 24311637
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg starting dose, maintenance dose between 12.5 mg and 50 mg depending on tolerability
Trial: 24314292
Drug: RARα antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: RARα antagonist Ro415253
Trial: 24314346
Drug: G-allele carriers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-allele carriers
Trial: 24315990
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor antagonist exendin (9-39) (Ex-9)
Trial: 24316314
Drug: Fermented Papaya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented Papaya Preparation (FPP) 6g/day for 14 weeks
Trial: 24319018
Drug: Detectable serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detectable serum AMH concentration at chemotherapy initiation
Trial: 24319462
Drug: Arthrocentesis using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis using saline and sodium hyaluronate injections
Trial: 24319489
Drug: Caraway extract
RxNorm normalized name: Caraway Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caraway extract (CE) 30 mL/day
Trial: 24320967
Drug: Oral mucosal
RxNorm normalized name: Finafta Multi Oral Mucosal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mucosal potentially malignant diseases (PMD) management
Trial: 24321746
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of third party bone marrow-derived mesenchymal stromal cells (MSC)
Trial: 24322398
Drug: β Blockers
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β Blockers
Trial: 24323026
Drug: Neratinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (200 mg) + Temsirolimus (25 mg)
Trial: 24323026
Drug: Neratinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (160 mg) + Temsirolimus (50 mg)
Trial: 24323468
Drug: Ertapenem dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem dosing regimens: 500 mg once daily, 750 mg once daily, 500 mg twice daily, and 1,000 mg once daily
Trial: 24324590
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg, every other day for 12 weeks
Trial: 24330670
Drug: Oral ATP
RxNorm normalized name: ATP
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ATP supplementation (400 mg per day)
Trial: 24330868
Drug: Lurasidone (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40-120 mg/day)
Trial: 24332512
Drug: Pidilizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidilizumab (3 mg/kg IV every 4 weeks for four infusions, plus eight optional infusions every 4 weeks) + Rituximab (375 mg/m² IV weekly for 4 weeks starting 17 days after first pidilizumab infusion)
Trial: 24334158
Drug: Prophylaxis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis with low-molecular-weight heparin or factor Xa-inhibitors only during hospitalisation when LOS ≤5 days.
Trial: 24334175
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg QD for 8 weeks in T1D-H group
Trial: 24334175
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg QD for 8 weeks in T1D-N group
Trial: 24335595
Drug: Cetuximab and
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab and radiotherapy (cetux-RT) added to perioperative chemotherapy (ECX)
Trial: 24335595
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (ECX)
Trial: 24337621
Drug: Aprepitant (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (125 mg on day 1, 80 mg on days 2-3), Ramosetron (0.6 mg on day 1), Dexamethasone (20 mg on day 1)
Trial: 24339028
Drug: Volasertib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volasertib (300 mg on day 1 every 3 weeks, escalated to 350 mg in cycle 2 if tolerated)
Trial: 24342300
Drug: pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pemetrexed (500 mg/m2 IV)
Trial: 24342300
Drug: docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel (75 mg/m2 IV)
Trial: 24342407
Drug: Non-selective endothelin
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective endothelin receptor antagonist
Trial: 24343893
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg every 12 h for 4 days) with rifapentine (900 mg once weekly for 3 weeks)
Trial: 24343893
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg every 12 h for 4 days) with rifapentine (600 mg once daily for 10 scheduled doses)
Trial: 24343893
Drug: Raltegravir alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir alone (400 mg every 12 h for 4 days)
Trial: 24344220
Drug: LMP-CTLs as
RxNorm normalized name: EBV-CTL
DrugBank: Tabelecleucel (DB17072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMP-CTLs as adjuvant therapy
Trial: 24347462
Drug: ABT-751 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-751 (200 mg/m² PO daily × 7 days every 21 days)
Trial: 24349052
Drug: Ataluren 4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ataluren 4, 4, 8 mg/kg three times per day
Trial: 24349052
Drug: Ataluren 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ataluren 20, 20, 40 mg/kg
Trial: 24349052
Drug: Ataluren (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ataluren (all doses)
Trial: 24349086
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g per day of ALA
Trial: 24349334
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily for 7 days
Trial: 24349470
Drug: PRS-050 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRS-050 at 0.1 mg/kg to 10 mg/kg by IV
Trial: 24349470
Drug: PRS-050 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PRS-050 infusion
Trial: 24351073
Drug: Serum CXCL-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CXCL-9 levels in antibody-positive women with a history of abortions
Trial: 24351073
Drug: Serum CXCL-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum CXCL-11 levels in antibody-positive women with a history of abortions
Trial: 24351336
Drug: lenalidomide monotherapy
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenalidomide monotherapy
Trial: 24351336
Drug: lenalidomide/cetuximab combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenalidomide/cetuximab combination treatment
Trial: 24352251
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/day as maintenance therapy after cCRT
Trial: 24352795
Drug: MLN8237 (alisertib)
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN8237 (alisertib) ECT 50 mg BID for 7 days in 21-day cycles
Trial: 24355090
Drug: Two-dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose schedule (M 0-6)
Trial: 24355090
Drug: Three-dose schedule
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose schedule (M 0-1-6)
Trial: 24355487
Drug: Anastrozole therapy
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole therapy
Trial: 24356623
Drug: Erlotinib 100
RxNorm normalized name: erlotinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 100 mg orally daily (maximally tolerated dose)
Trial: 24356623
Drug: Erlotinib added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib added to infusional 5-FU 225 mg/M2/day, bevacizumab 5 mg/kg, and radiation 50.4 Gy in 28 fractions
Trial: 24356628
Drug: High p-AKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High p-AKT expression group with concurrent Epstein-Barr virus positivity
Trial: 24356787
Drug: PHiD-CV booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHiD-CV booster dose co-administered with DTPa booster dose
Trial: 24356787
Drug: 2-dose catch-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose catch-up with PHiD-CV (first dose co-administered with DTPa booster dose)
Trial: 24358067
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac SR 75 mg twice daily plus omeprazole 20 mg daily
Trial: 24359635
Drug: New antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antipsychotic monotherapy treatment initiated within 2 weeks prior to enrollment
Trial: 24359635
Drug: New antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antipsychotic monotherapy treatment
Trial: 24359972
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (max CGM glucose value ≥ 11 mmol/l)
Trial: 24359972
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (max CGM glucose value < 11 mmol/l)
Trial: 24360789
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment, mean final dose 0.6 (0.25) mg
Trial: 24361681
Drug: Ritonavir-boosted darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted darunavir monotherapy (MtDRV/rtv)
Trial: 24362550
Drug: Triapine (105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triapine (105 mg/m²/day) followed by fludarabine (30 mg/m²/day) daily for 5 consecutive days
Trial: 24363672
Drug: Chemomechanical caries
RxNorm normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemomechanical caries removal with Papacarie gel
Trial: 24363760
Drug: Oral arginine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral arginine, peripheral TPN
Trial: 24366423
Drug: Erythritol 36
RxNorm normalized name: Erythritol
DrugBank: Erythritol (DB04481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythritol 36 g/day as an orange-flavored beverage for 4 weeks
Trial: 24366583
Drug: Melatonin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (4 mg) twice daily until birth
Trial: 24368064
Drug: Twice-weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly gemcitabine (starting dose 15 mg/m², escalated to 20, 25, and 30 mg/m²) and cisplatin (CDDP 20 mg/m²/day over 4 days every 21 days) with concomitant radiation therapy (63 Gy in 1.8 fractions)
Trial: 24368064
Drug: Twice-weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly gemcitabine (30 mg/m²)
Trial: 24369094
Drug: Belinostat (PXD101)
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belinostat (PXD101) administered intravenously at a dose of 1000 mg/m² daily on days 1-5 of a 21-day cycle until progression or unacceptable toxicity.
Trial: 24369412
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg adalimumab every other week
Trial: 24372730
Drug: Salvage partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage partial low-dose rate brachytherapy
Trial: 24372730
Drug: Initial low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial low-dose rate brachytherapy
Trial: 24373120
Drug: Caspofungin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin + liposomal amphotericin B (L-AmB)
Trial: 24373120
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (combo)
Trial: 24373343
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (estrogen-alone and estrogen plus progestin)
Trial: 24375324
Drug: Waist and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waist and subcutaneous adipose tissue (SAT)
Trial: 24377099
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine in Montanide adjuvant
Trial: 24377099
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine in Montanide adjuvant with GM-CSF
Trial: 24378417
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg/day by mouth for up to 12 months, with possible dose escalation to 600 mg/day at 3 months if stable.
Trial: 24379928
Drug: Rosuvastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin monotherapy (40 mg/d)
Trial: 24380752
Drug: drug-targeting nebulization
RxNorm normalized name: NEBULIZER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug-targeting nebulization
Trial: 24381190
Drug: Pre-bronchodilator FEV1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-bronchodilator FEV1
Trial: 24381226
Drug: Otlertuzumab administered
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Otlertuzumab administered intravenously, ranging from 0.03 to 20 mg/kg in dose-escalation phase and 10 to 30 mg/kg in dose-expansion phase, weekly for up to 8 weeks followed by 1 dose per month for 4 months.
Trial: 24383664
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate supplementation (220 mg per capsule, 2 capsules per day for 3 months)
Trial: 24383664
Drug: Fertile controls
RxNorm normalized name: Tests for fertility disturbances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fertile controls (no treatment)
Trial: 24384108
Drug: 14-day adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day adhesive patch monitor
Trial: 24384609
Drug: Budesonide 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 1,500 μg
Trial: 24384609
Drug: Budesonide 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 1,500 μg (in cases with high baseline clinical score ≥13)
Trial: 24385516
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (B6) administered orally starting at 5 mg/kg body weight per day, increasing by 5 mg/kg every 6 weeks up to 20 mg/kg per day at week 24.
Trial: 24386300
Drug: Budesonide/formoterol 400/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 400/12 µg twice a day for 4 weeks